hVIVO Holdings Ltd is a United Kingdom-based company. The Company is engaged in sciences business pioneering a technology platform of human disease models to accelerate drug discovery and in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.

Employees

Sector

Healthcare Facilities & Services

More about the company

Delayed London S.E.			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

09-15	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-15	HVIVO CFO to Step Down; Interim CFO Named	MT

Market Cap	13.8M 18.46M 16.54M 15.25M 25.81M 1.76B 26.23M 182M 72.61M 920M 69.28M 67.81M 2.91B	P/E 2023	7.02x	P/E 2024	10.6x
Enterprise Value	-17.47M -23.37M -20.93M -19.31M -32.68M -2.23B -33.2M -230M -91.91M -1.16B -87.7M -85.83M -3.69B	EV / Sales 2023	-0.19x	EV / Sales 2024	-0.28x
Free-Float	91.04%	Yield 2023	1.21%	Yield 2024	1.21%

09-15	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-15	HVIVO CFO to Step Down; Interim CFO Named	MT
09-15	Earnings Flash (HVO.L) hVIVO plc Reports H1 Revenue GBP16.3M	MT
09-15	Earnings Flash (HVO.L) hVIVO plc Posts H1 Loss GBX-0.94	MT
08-27	HVIVO Acquires German Research Institute CRS Clinical Research	MT
05-07	HVIVO Secures GBP6 Million Deal to Run Influenza Human Challenge Trial for Monoclonal Antibody	MT
04-22	HVIVO to Run Late-stage Human Challenge Trial for ILiAD's Whooping Cough Vaccine Candidate	MT
04-15	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Hvivo plc Signs Clinical Trial Agreement with Traws Pharma	CI
04-14	HVIVO to Run Phase 2a Influenza Challenge Trial for Traws Pharma's Antiviral Candidate	MT
25-09-23	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-29	Hvivo Names New Nonexecutive Chairman	MT
25-04-10	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI

25-02-04	Inhalon Biopharma Announces First-of-its-Kind Inhaled Antibody Treatment for RSV to Enter Human Clinical Trials	AQ
24-04-09	HVIVO achieves record revenue and initiates dividend policy following successful year	AQ
24-02-20	HVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale	AQ
24-01-02	HVIVO secures Ã‚£6.3 million challenge contract	AQ
23-12-13	HVIVO secures fresh contract to round out "wonderful" year	AQ

hVIVO plc Stock

Stocks

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Valuation: hVIVO plc

Latest news: hVIVO plc

Press Releases: hVIVO plc

News in other languages: hVIVO plc

Managers and Directors: hVIVO plc

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

21-02-17	WDH/Britische Wissenschaftler wollen Freiwillige mit Corona infizieren
20-09-25	Absichtliche Corona-Infektionen: Ein guter Weg zum Impfstoff?

Manager	Title	Age	Since
Mohammed Khan CEO	Chief Executive Officer	57	2022-01-31
Stephen Pinkerton DFI	Director of Finance/CFO	63	-
Thomas Andreas Forst CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Cathal Friel CHM	Chairman	62	2020-03-31
Brendan Buckley BRD	Director/Board Member	76	-
Mohammed Khan BRD	Director/Board Member	57	2022-01-31

Date	Insider	Type	Quantity	% Market Cap.
10/11/24	Yamin Khan	Free	4,606,794	5.5106%
6/14/23	Yamin Khan	Buy	13,526	0.0162%
2/6/23	Yamin Khan	Free	7,227,273	8.6452%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HVIVO PLC	-.--%	+18.92%	-	-	18.04M
CVS HEALTH CORPORATION	+0.42%	-4.39%	+12.07%	+36.26%	115B
HCA HEALTHCARE, INC.	+3.21%	+2.30%	+2.07%	+112.21%	100B
NATERA, INC.	+2.73%	+8.63%	+126.13%	+1,039.57%	61.18B
FRESENIUS SE & CO. KGAA	+0.17%	+1.62%	-6.81%	+89.51%	29.09B
LABCORP HOLDINGS INC.	+2.20%	+11.59%	+48.37%	+85.04%	29.25B
QUEST DIAGNOSTICS INCORPORATED	+2.97%	+3.96%	+44.71%	+98.09%	27.02B
TENET HEALTHCARE CORPORATION	+0.77%	-0.02%	+29.37%	+409.36%	21.62B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.72%	+5.53%	-18.98%	-7.55%	20.81B
IHH HEALTHCARE	+0.26%	-1.75%	-4.85%	+31.49%	16.97B
Average	+1.20%	+3.74%	+25.79%	+210.44%	42.13B
Weighted average by Cap.	+1.64%	+0.81%	+28.24%	+227.86%

	2023	2024
Net sales	56.04M 74.95M 67.13M 61.93M 105M 7.14B 106M 739M 295M 3.74B 281M 275M 11.83B	62.72M 83.88M 75.13M 69.31M 117M 7.99B 119M 827M 330M 4.18B 315M 308M 13.24B
Net income	16.11M 21.55M 19.3M 17.81M 30.13M 2.05B 30.62M 212M 84.76M 1.07B 80.88M 79.15M 3.4B	10.65M 14.24M 12.76M 11.77M 19.92M 1.36B 20.24M 140M 56.02M 710M 53.46M 52.32M 2.25B
Net Debt	-24.44M -32.69M -29.28M -27.01M -45.71M -3.11B -46.45M -322M -129M -1.63B -123M -120M -5.16B	-31.28M -41.83M -37.47M -34.57M -58.49M -3.98B -59.44M -412M -165M -2.08B -157M -154M -6.6B